Daniel G. Welch

Mr. Welch joined Ultragenyx as a board member in April 2015. Mr. Welch was an Executive Partner at Sofinnova Ventures from January 2015 through January 2018. Prior to Sofinnova, Mr. Welch served as Chairman, Chief Executive Officer and President of InterMune from May 2008 to October 2014 and served as President and Chief Executive Officer of Intermune and a member of its board of directors from September 2003 to May 2008. From August 2002 to January 2003, Mr. Welch served as Chairman and Chief Executive Officer of Triangle Pharmaceuticals, Inc. From October 2000 to June 2002, Mr. Welch served as president of the pharmaceutical division of Elan Corporation, PLC. Mr. Welch also currently serves as chairman of the board of AveXis, Inc., and serves on the boards of directors of Seattle Genetics, Inc. and Intercept Pharmaceuticals, Inc. He holds a B.S. from the University of Miami and an M.B.A. from the University of North Carolina.